Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neuroendocrine Tumors 1Mouth Neoplasms 1Lymphatic Metastasis 1Locally Advanced Rectal Cancer 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyosarcoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Dermatofibrosarcoma 1Cholangiocarcinoma 1Carcinoma 1Advanced Solid Tumors 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Neoplasms × peposertib × Clear all
NCT04092270 2026-05-13

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
54 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT03724890 2025-04-10

Study of Avelumab-M3814 Combinations

EMD Serono

Phase 1 Completed
57 enrolled 56 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡